Search results
Results from the 24/7 Vacations Content Network
In March 2020, then US President Donald Trump promoted the use of chloroquine and hydroxychloroquine, two related anti-malarial drugs, for treating COVID-19. The FDA later clarified that it has not approved any therapeutics or drugs to treat COVID-19, but that studies were underway to see if chloroquine could be effective in treatment of COVID-19.
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria[6]and Covishield,[7]is a viral vector vaccine[8]produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. [8][9][10]Finland, Denmark, and Norway suspended the use of the Oxford ...
In the European Union, remdesivir is indicated for the treatment of COVID‑19 in adults and adolescents (aged twelve years and older with body weight at least 40 kilograms (88 lb)) with pneumonia requiring supplemental oxygen and for adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19.
Bolthouse Farms, the maker of juices and dressings, is offering its employees a $500 bonus if they get vaccinated at one of the company’s on-site clinics or can show proof of vaccination. Yogurt ...
Health officials set aside carefully considered plans for rolling out COVID-19 vaccines and made the shots widely available. That may hasten the pandemic's end. How the new COVID-19 vaccine rules ...
For premium support please call: 800-290-4726 more ways to reach us
The vaccine may have characteristics favorable for vaccinating people in the developing world. While mRNA vaccines, such as the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of +90%, mRNA vaccines present distribution challenges for some nations, as some may require deep-freeze facilities and trucks.
The FDA also said it will hold another meeting of its advisers in June to discuss the strain composition of the COVID-19 vaccines for the fall season, with mRNA vaccine manufacturers expected to ...